Evidence map›Paper›PMID 35510091›Full record

ArticleTherapeutic advances in infectious disease

Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with

Alpesh Amin, Winnie W Nelson, Jill Dreyfus, Anny C Wong, Iman Mohammadi, Christie Teigland, David N Dahdal, Paul Feuerstadt

Abstract read
In one paragraph

Article in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Investigating the Effects of NosocomialHCA healthcare journal of medicine · 2024
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alpesh AminUCI Medical Center, 101 The City Drive, City Tower, Suite 500, Orange, CA 92868, USA.ORCID https://orcid.org/0000-0002-9790-0245
Winnie W NelsonFerring Pharmaceuticals Inc., Parsippany, NJ, USA.
Jill DreyfusAvalere Health, Washington, DC, USA.
Anny C WongAvalere Health, Washington, DC, USA.
Iman MohammadiAvalere Health, Washington, DC, USA.
Christie TeiglandAvalere Health, Washington, DC, USA.
David N DahdalFerring Pharmaceuticals Inc., Parsippany, NJ, USA.
Paul FeuerstadtPACT Gastroenterology Center, Hamden, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To describe mortality, healthcare resource utilization (HRU), and costs among Medicare beneficiaries with primary Methods: We conducted a retrospective observational study of 100% Medicare Fee-for-Service claims from adults aged ⩾ 65 years with ⩾1 CDI episode between 1 January 2009 and 31 December 2017. Patients were continuously enrolled in Medicare Parts A/B/D 12 months before and up to 12 months after pCDI. ICD-9/10 codes defined CDI using ⩾1 inpatient claim, or ⩾1 outpatient claim plus ⩾1 claim for CDI treatment. The pCDI episode ended after 14 days without a CDI claim. rCDI episodes started within 8 weeks from the end of a previous CDI episode. ICD-9/10 codes identified all-cause sepsis over 12 month follow-up. Results: Of 497,489 CDI patients, 41.0% ( Conclusions: Sepsis was common among Medicare beneficiaries with CDI. CDI patients with sepsis, especially after an rCDI, experienced higher mortality, HRU, and costs compared with those without sepsis.

Indexed as

Clostridioides difficileClostridium difficile infectioncosthealthcare resource utilizationMedicarerecurrent CDIsepsis

Identifiers

PMID35510091
PMCPMC9058456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.